Publication
Decisões clínicas na doença de Crohn
| dc.contributor.author | Magro, F | |
| dc.contributor.author | Correia, L | |
| dc.contributor.author | Lago, P | |
| dc.contributor.author | Macedo, G | |
| dc.contributor.author | Peixe, P | |
| dc.contributor.author | Portela, F | |
| dc.contributor.author | Ferreira, A | |
| dc.contributor.author | Gonçalves, R | |
| dc.contributor.author | et al | |
| dc.date.accessioned | 2013-04-05T14:02:33Z | |
| dc.date.available | 2013-04-05T14:02:33Z | |
| dc.date.issued | 2012 | |
| dc.description.abstract | Introduction: Crohn s disease is a chronic inflammatory disease from gastrointestinal tract. The increase in incidence and heterogeneity of this pathology, with different presentations and prognostics leads to a constant concern in developing and improving its classification and treatment. Objectives: To establish recommendations (based on level of evidence and recommendation grades) to 5 questions considered as the clinical challenges of the therapeutic approach in Crohn s disease. Methods: The methodology adopted by the working group DC2 (Desafios Clínicos na Doença de Crohn) was based on the selection of 5 questions, by voting, and establishing recommendations to each question proposed to each subgroup. Discussion and approval of reflexions and final recommendations was carried out in a consensus meeting. Conclusion: It has been possible to base conclusions about the questions under study on evidence, being recommended: 1) having Crohn s disease under 40 years old, structuring phenotype disease and anal disease are predictive factors of bad prognostic; 2) it is possible to consider suspension of biologics in patients with endoscopic remission and normal biomarkers; 3) patients with biochemical markers of disease activity (CRP and calprotectina) have more probability of relapse; 4) in failure of biologics it is essential to assure that treatment with the first drug was optimized: with infliximab it s demonstrated that either reduction of the administration range or increasing the dose allows to recover the response in the majority of patients; as for adalimumab, patients should change from bimonthly to weekly administrations; 5) in case of Crohn s disease with intestinal surgery, use of therapeutic to reduce postoperative recurrence is indicated, particularly immunosupressors and biologics. | por |
| dc.identifier.citation | J Port Gastrenterol.2012;19(2):71-88 | por |
| dc.identifier.uri | http://hdl.handle.net/10400.23/418 | |
| dc.language.iso | por | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Sociedade Portuguesa de Gastrenterologia | por |
| dc.subject | Doença de Crohn | por |
| dc.title | Decisões clínicas na doença de Crohn | por |
| dc.title.alternative | linical challenges in Crohn s disease | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |